Celcuity (NASDAQ:CELC) Stock Rated Overweight in New Coverage at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Celcuity (NASDAQ:CELC) in a research note released on Thursday, MarketBeat.com reports. The brokerage issued an overweight rating and a $140.00 target price on the stock.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a report on Tuesday, September 1st. Craig Hallum reissued a “buy” rating and set a $178.00 price target on shares of Celcuity in a research report on Wednesday, July 15th. HC Wainwright restated a “buy” rating and issued a $155.00 price target on shares of Celcuity in a report on Friday, August 14th. Zacks Research downgraded shares of Celcuity from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 13th. Finally, Guggenheim increased their price objective on shares of Celcuity from $165.00 to $175.00 and gave the company a “buy” rating in a research report on Monday, August 17th. Thirteen equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Celcuity has an average rating of “Moderate Buy” and an average price target of $152.57.

Celcuity Stock Down 0.5%

Shares of NASDAQ CELC opened at $65.25 on Thursday. Celcuity has a 12-month low of $53.54 and a 12-month high of $151.02. The company has a market cap of $3.19 billion, a P/E ratio of -15.17 and a beta of 0.10. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04. The stock has a fifty day moving average price of $80.14 and a 200 day moving average price of $98.04.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.28). Research analysts anticipate that Celcuity will post -4.98 EPS for the current fiscal year.

Institutional Trading of Celcuity

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC bought a new position in Celcuity during the 4th quarter valued at $1,058,000. California State Teachers Retirement System grew its holdings in Celcuity by 91.2% during the 1st quarter. California State Teachers Retirement System now owns 25,580 shares of the company’s stock worth $2,920,000 after acquiring an additional 12,201 shares in the last quarter. Bank of America Corp DE acquired a new position in Celcuity during the 2nd quarter worth $153,928,000. E Fund Management Co. Ltd. bought a new stake in shares of Celcuity in the 2nd quarter worth about $4,802,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Celcuity in the 2nd quarter worth about $2,927,000. Institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company’s CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.